MicroRNAs as molecular biological markers of benign hyperplasia and prostate cancer differentiation
Diagnosis and treatment of prostate cancer (PCа) are associated with the serum level of prostate specific antigen (PSA). However, certain prostate diseases such as benign prostatic hyperplasia (BPH) and prostatitis can also affect PSA levels. The low specificity and sensitivity of PSA leads to a &qu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation
2023-10-01
|
| Series: | Vestnik Urologii |
| Subjects: | |
| Online Access: | https://www.urovest.ru/jour/article/view/760 |
| Summary: | Diagnosis and treatment of prostate cancer (PCа) are associated with the serum level of prostate specific antigen (PSA). However, certain prostate diseases such as benign prostatic hyperplasia (BPH) and prostatitis can also affect PSA levels. The low specificity and sensitivity of PSA leads to a "unnecessary" prostate biopsy, which certainly makes this diagnostic method a controversial screening test. As a result, the discovery of new non-invasive molecular biological markers are necessary for the diagnosis, treatment, surveillance and prognosis of patients with diseases of prostate. This review aims to evaluate the "benefit" of miRNAs as molecular biological markers of BPH and PCa differentiation. |
|---|---|
| ISSN: | 2308-6424 |